Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

Players Still ‘Fragmented And Segmented’

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

Bio Korea 2025
Korea Still Needs Relevant Legal Arrangements In AI Drug Development

More from South Korea

More from Conferences